First Two Cases of Infected Aortic Aneurysm Caused by Non-Vaccine *Streptococcus pneumoniae* Serotype 23A

Risako Kakuta (a), M.D., Ph.D.,1 Ryuichi Nakano (a), Ph.D.,2 Hisakazu Yano (a), M.D., Ph.D.,3 Daiki Ozawa (a), M.D., Ph.D.,1 Nobuo Ohta (a), M.D., Ph.D., Takayuki Matsuoka (a), M.D., Ph.D.,4 Naotaka Motoyoshi (a), M.D., Ph.D.,5 Shunsuke Kawamoto (a), M.D., Ph.D.,4 Yoshikatsu Saiki (a), M.D., Ph.D.,5 Yukio Katori (a), M.D., Ph.D.,1 and Mitsuo Kaku (a), M.D., Ph.D.6,7

1Department of Otolaryngology-Head and Neck Surgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan; 2Department of Microbiology and Infectious Diseases, Nara Medical University, Kashihara, Nara, Japan; 3Division of Otolaryngology, Tohoku Medical and Pharmaceutical University, Sendai, Miyagi, Japan; 4Division of Cardiovascular Surgery, Tohoku Medical and Pharmaceutical University, Sendai, Miyagi, Japan; 5Division of Infectious Diseases, Internal Medicine, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan; 6Division of Infectious Diseases and Infection Control, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Miyagi, Japan

Dear Editor,

Infected aortic aneurysm (IAA) is an uncommon, but life-threatening condition. Identification of the causative pathogen is essential for accurate diagnosis and effective treatment. However, 14–40% of IAA cases are culture-negative [1]. IAA due to *Streptococcus pneumoniae* is rare, and reports of the involvement of S. pneumoniae capsular serotypes and sequence types (STs) in IAA are even rarer [2-5]. We identified S. pneumoniae from culture-negative IAA by genetic analysis. To the best of our knowledge, as of 2019, only 59 cases of pneumococcal IAA have been reported in France, the United Kingdom (UK), the Netherlands, Germany, Switzerland, Belgium, Denmark, the United States (USA), Canada, Chile, Japan, Hong Kong, Korea, and Austria since 1977 [2-5]. In the previous cases of IAA due to S. pneumoniae, capsular serotype analysis was reported only for seven: 10A and 23F in the UK, 4 and 8 in Denmark, 19F in Hong Kong, 4 in Belgium, and 23 in USA [2-5]. We report the first two cases of culture-negative IAA due to non-vaccine S. pneumoniae serotype 23A, ST338. The study protocol was approved by the Institutional Ethics Committees of Tohoku University, Sendai, Japan (No. 2018-1-456).

Case 1 was of a 68-year-old female treated in 2017 for three aneurysms in the thoracic aorta. Case 2 was of a 70-year-old male treated in 2014 for a ruptured pararenal aortic aneurysm. Informed consent was obtained from the patient in case 1, and in case 2, research information has been disclosed in accordance with the ethical guidelines for Medical and Health Research Involving Human Subjects established by the Japanese Ministry of Health, Labor and Welfare (https://www.mhlw.go.jp/stf/seisakuinsuite/bunya/hokabunya/kenkyujigyoui-kenkyu/index.html). Both patients had no history of disease-causing immune deficiency or pneumococcal vaccination and underwent surgical treatment. In case 1, the two larger aneurysms were resected during staged surgeries. In case 2, the aneurysm ruptured, leading to abscess formation in the anterior cavity of the iliopsoas muscle, and left renal artery was reconstructed owing to...
to occlusion.

As the blood and tissue cultures were negative in both cases, 16S ribosomal RNA gene analysis of tissue was performed as described previously [1]. In both cases, the sequence similarity was the highest with *S. pneumoniae*, and species identification was further confirmed by amplification of the lytA region, which is specific to *S. pneumoniae* [6]. In case 1, *S. pneumoniae* was identified in two separate aneurysms. Oral antibiotics were prescribed for both patients at discharge, and no recurrence has been reported.

The serotype of the *S. pneumoniae* isolated from each patient was identified as 23A following the US Centers for Disease Control and Prevention protocols for conventional PCR (https://www.cdc.gov/streplab/pneumococcus/resources.html) [7]. Multilocus

| Variables                                      | Case 1                                      | Case 2                                      |
|------------------------------------------------|---------------------------------------------|---------------------------------------------|
| Age (yr), Sex                                  | 68, Female                                  | 70, Male                                    |
| Underlying diseases                           | Sigmoid colon cancer (postoperative), hypertension | Bronchial asthma, hypertension, hyperuricemia, hyperlipidemia |
| Risk factors for infection                    | None                                        | None                                        |
| Pneumococcal vaccination history              | None                                        | None                                        |
| Clinical presentation                         | Fever, back pain                            | Fever, lumbar pain                          |
| Site of aneurysm (size in mm; by CT)          | Ascending aorta (58), descending aorta (34, < 30) | Pararenal (40)                             |
| Inflammation around aneurysm (CT)             | Positive (observed in the two larger aneurysms) | Positive                                   |
| Maximum temperature before surgery (°C)       | 37.5                                        | 38.4                                        |
| Maximum white blood count (× 10^9/L) before surgery | 8.4                                          | 15.5                                        |
| Maximum C-reactive protein (nmol/L) before surgery | 1,104.8                                      | 1,695.3                                     |
| Surgical management                           | *In situ* grafting                          | *In situ* grafting                          |
| Microbiological diagnosis                     |                                             |                                             |
| Blood culture                                 | Negative                                    | Negative                                    |
| Tissue culture                                | Negative                                    | Negative                                    |
| 16S rRNA gene sequence similarity*            | 99.64%                                      | 99.86%                                      |
| lytA (specific to *S. pneumoniae*)            | Positive                                    | Positive                                    |
| Serotype                                      | 23A                                         | 23A                                         |
| MLST                                           | ST338 (CC 156)                              | ST338 (CC 156)                              |
| Alterations in PBP genes                      | Positive (pbp2x and pbp2b)                  | Positive (pbp2x and pbp2b)                  |
| Amino acid substitutions in QRDR (GyrA and ParC) | None                                        | None                                        |
| Anti-microbial therapy                         |                                             |                                             |
| Before admission                               | None                                        | Ceftriaxone                                  |
| After admission                                | Vancomycin (0.75→2.5 g/day) and gentamicin (150 mg/day) | Piperacillin-tazobactam (9 g/day) and vancomycin (1 g/day), then teicoplanin (400→200 mg/day) |
| After identification of the pathogen           | Sulbactam-ampicillin (6 g/day) and levofloxacin (500 mg/day) | Sulbactam-ampicillin (9 g/day)              |
| At discharge                                   | Oral amoxicillin (750 mg/day) and levofloxacin (500 mg/day) | Oral amoxicillin (1,500 mg/day)             |
| Hospital treatment period (days)               | 60                                          | 61                                          |
| Postoperative complications                    | None                                        | Mild decline in renal function              |
| Outcome                                        | Alive                                       | Alive                                       |

*Compared with *S. pneumoniae* type strains NCTC 7465¹ (case 1) and ATCC 33400¹ (case 2); ¹Vancomycin started at 0.75 g/day and increased to 2.5 g/day; ²Teicoplanin started at 400 mg/day and decreased to 200 mg/day. Abbreviations: rRNA, ribosomal RNA; CC, clonal complex; CT, computed tomography; MLST, multilocus sequence typing; QRDR, quinolone resistance-determining region; ST, sequence type; PBP, penicillin binding protein; NCTC, National Collection of Type Cultures; ATCC, American Type Culture Collection.
sequence typing (MLST) analysis was performed according to the *S. pneumoniae* MLST Database (https://pubmlst.org/spneu- moniae/); in both cases, *S. pneumoniae* was identified as ST338, clonal complex 156. Alterations in *pbp2x* and *pbp2b*, genes encoding penicillin-binding protein that mediate β-lactam resistance in *S. pneumoniae*, were identified in both cases [8]. Mutations in the quinolone resistance-determining region of *gyrA* and parC, which are important determinants of levofloxacin resistance [9], were not detected in either case. The clinical and molecular characteristics of both cases are detailed in Table 1.

In Japan, the 7-valent pneumococcal conjugate vaccine (PCV7) was introduced for children younger than five yrs in 2010 and was replaced with PCV13 in 2013. In 2014, the 23-valent pneumococcal polysaccharide vaccine was introduced for vaccination in adults over 65 years. Depending on the effect of vaccination, reduced carriage and incidence of invasive pneumococcal disease (IPD) and increased prevalence of non-vaccine serotypes (NVTs) in IPD cases have been reported [10]. According to recent Japanese surveillance studies, the proportion of IPD cases attributed to serotype 23A (an NVT) has been increasing since the introduction of PCVs [10]. More than 90% of 23A isolates from adult IPD cases showed alterations in *pbp2x* and *pbp2b*, and approximately a half of them were reported as ST338, similar to the isolates in the current cases. Genetic analysis of the isolates in our cases indicated susceptible to levofloxacin, as reported in previous IPD cases in Japan [10]. Although the current cases were successfully treated, the isolates were NVTs and harbored *pbp2x* alterations, making them resistant to cephems. As cephem antibiotics are used frequently in Japan, there is a concern that antibiotic selection pressure will lead to an increase in the proportion of drug-resistant isolates. Moreover, with the introduction of PCVs, there is also a concern regarding the relative increase in NVTs and drug-resistant isolates.

In conclusion, we identified 23A *S. pneumoniae*, ST338, in culture-negative IAA for the first time in two independent cases, raising the concern that NVT and drug-resistant pneumococci may exist in culture-negative IAA cases. Further epidemiological studies and investigation of preventive measures for IPD, including IAA, are required.

**AUTHOR CONTRIBUTIONS**

RK wrote the manuscript; TM, NM, SK, and YS treated patients and collected samples; RK, RN, HY, and DO conducted the laboratory work, described the associated process, and interpreted the results; NO, YK, and MK contributed to the writing of the manuscript.

**CONFLICTS OF INTEREST**

No potential conflicts of interest relevant to this article were reported.

**RESEARCH FUNDING**

None declared.

**ORCID**

Risako Kakuta https://orcid.org/0000-0002-4594-908X
Ryuichi Nakano https://orcid.org/0000-0003-2086-2591
Hisakazu Yano https://orcid.org/0000-0003-2085-7194
Daiki Ozawa https://orcid.org/0000-0003-2099-0198
Nobuo Ohta https://orcid.org/0000-0002-2821-6976
Takayuki Matsuoka https://orcid.org/0000-0002-7658-4829
Naotaka Motoyoshi https://orcid.org/0000-0002-6950-1343
Shunsuke Kawamoto https://orcid.org/0000-0001-8748-3567
Yoshikatsu Saiki https://orcid.org/0000-0003-0959-7133
Yukio Katori https://orcid.org/0000-0001-8875-1652
Mitsuo Kaku https://orcid.org/0000-0002-3714-8100

**REFERENCES**

1. Kakuta R, Yano H, Kanamori H, Shimizu T, Gu Y, Hatta M, et al. *Helicobacter cinaedi* infection of abdominal aortic aneurysm, Japan. Emerg Infect Dis 2014;20:1942-5.
2. Nijs A, Vandekerckhof J, Cartuyvels R, Magerman K, Mewis A, Peeters V, et al. *Streptococcus pneumoniae*-infected aortic aneurysm extending from a persistent lobar pneumonia: case report and review of the literature. Eur J Clin Microbiol Infect Dis 2002;21:389-92.
3. Watura K, Katsimhas M, Williams M. *Streptococcus pneumoniae* mycotic aneurysm with contiguous vertebral discsitis treated by endovascular aortic repair and antibiotics. BMJ Case Rep 2013;2013:bcr2012008499.
4. Chan JF, Hwang GY, Lamb S, Chan GS, So JC, Leung SS, et al. Pneumococcal native aortic valve endocarditis with mycotic abdominal aortic aneurysm, parasplenic and iliopsoas absceses and pneumonia revealing a multiple myeloma. J Med Microbiol 2011;60:851-5.
5. Sintler M, Howell N, Mahmood A, Vohra RK. Ruptured inflammatory aortic aneurysm with aortenteric fistula and infected with *Streptococcus pneumoniae*: a review of the literature. Indian J Surg 2008;70:138-41.
6. Ubuukata K, Asahi Y, Yamane A, Konno M. Combinational detection of autolysin and penicillin-binding protein 2B genes of *Streptococcus pneumoniae* by PCR. J Clin Microbiol 1996;34:592-6.
7. da Gloria Carvalho M, Pimenta FC, Jackson D, Roundtree A, Ahmad Y, Millar EV, et al. Revisiting pneumococcal carriage by use of broth enrichment and PCR techniques for enhanced detection of carriage and serotypes. J Clin Microbiol 2010;48:1611-8.
8. Ubukata K, Chiba N, Hasegawa K, Kobayashi R, Iwata S, Sunakawa K. Antibiotic susceptibility in relation to penicillin-binding protein genes and serotype distribution of *Streptococcus pneumoniae* strains responsible for meningitis in Japan, 1999 to 2002. Antimicrob Agents Chemother 2004;48:1488-94.

9. Takeuchi N, Ohkusu M, Hoshino T, Naito S, Takaya A, Yamamoto T, et al. Emergence of quinolone-resistant strains in *Streptococcus pneumoniae* isolated from paediatric patients since the approval of oral fluoroquinolones in Japan. J Infect Chemother 2017;23:218-23.

10. Ubukata K, Takata M, Morozumi M, Chiba N, Wajima T, Hanada S, et al. Effects of pneumococcal conjugate vaccine on genotypic penicillin resistance and serotype changes, Japan, 2010–2017. Emerg Infect Dis 2018;24:2010-20.